About US
Contact us
-
Biogen MS pill soars onstage with impressive first-week script numbersBiogen Idec's ($BIIB) newmultiple sclerosispill made its debut to high expectations earlier this month. And so far, Tecfidera hasn't disappointed. AsThe Streetreports, the drug has literally leapt on2013/4/24
-
New tool for live cell imaging launchedA new tool for live cell imaging has been announced by Cellectis bioresearch - a subsidiary of Cellectis Group. VizuCELL cell lines is set to help with the study of temporal and spatial dynamic proces2013/4/23
-
AstraZeneca inks cancer deals with Bind Therapeutics, Horizon DiscoveryAstraZeneca ($AZN) forged two oncology development deals on either side of the Atlantic. It teamed up with the U.K.'s Horizon Discovery on a program to target K-Ras mutant tumors, and tapped Bind The2013/4/23
-
First implantation of resorbable antibacterial envelope announcedThe first ever implantation of a fully resorbable antibacterial envelope has taken place to help ensure surgery patients are at a lower risk of infection. According to TYRX, the AIGISRx R antibacteri2013/4/22
-
Hated German price formula to be applied to Pradaxa, Prolia, other drugsDrugmakers, livid with German pricing gatekeepers for turning down so many new drugs, now face a strategy that is sure to ratchet up their anger to the boiling point. The agency has started a review2013/4/22
-
Hikma decides injectables drug business a prize to hold ontoWhen Mylan agreed to pay $1.6 billion to nab Strides Arcolab's sterile injectables drug business, the competitors it bested were thought to be sniffing around elsewhere for a similar deal. Within d2013/4/19
-
Yin Li meets Deputy Director General of New Zealand Ministry for Primary IndustriesOn the afternoon of April 16, 2013, Yin Li met with Ms. Carole Barnao, Deputy Director General of New Zealand Ministry for Primary Industries, and her entourage. Both sides introduced the main respons2013/4/19
-
Supreme Court exposes GlaxoSmithKline to Humana's Avandia-spending claimsThe U.S. Supreme Court declined to consider an appeal from GlaxoSmithKline ($GSK) in a fight over Humana's spending on the company's disgraced diabetes drug Avandia. The ruling not only opens GSK t2013/4/17
-
FDA puts halt to generic OxyContinFor months FDA regulators have been wrestling with the dangers of allowing a flood of cheap, generic versions of the highly addictive OxyContin on the market versus the benefit of consumers with pa2013/4/17
-
AbbVie to hack hundreds of reps from cardiovascular sales ranksAbbVie ($ABBV) has a new distinction. It may be the youngest pharma company ever to lay off hundreds of salespeople. Bloomberg reports that the drugmaker, spun off by Abbott Laboratories ($ABT) as2013/4/16